-+ 0.00%
-+ 0.00%
-+ 0.00%

Zai Lab starts Phase 1/1b trial of ZL-1503 bispecific antibody in atopic dermatitis

PUBT·04/18/2026 13:00:22
Listen to the news
Zai Lab starts Phase 1/1b trial of ZL-1503 bispecific antibody in atopic dermatitis
  • Zai Lab announced new preclinical data on ZL-1503, an IL-13/IL-31Rα bispecific antibody being developed for moderate-to-severe atopic dermatitis and other atopic diseases.
  • Results were presented in a poster session at IMMUNOLOGY2026 on April 18, 2026.
  • Study readouts indicated rapid itch relief with sustained suppression of inflammation, supporting potential first-in-class positioning.
  • Nonclinical safety findings were described as supportive of moving into human testing.
  • Zai Lab initiated Phase 1/1b first-in-human studies in December 2025 in Australia, New Zealand, and China in healthy volunteers and adults with moderate-to-severe atopic dermatitis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260418529898) on April 18, 2026, and is solely responsible for the information contained therein.